<description>&lt;p&gt;Access to compounded and research-grade GLP-1s may be tightening, as comments from Robert F. Kennedy Jr. signal increased enforcement and a push back toward branded medications. At the same time, new data on retatrutide shows powerful results for people with type 2 diabetes, while drug companies are already developing next-generation therapies beyond GLP-1s. &lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Todat&amp;#39;s topics:&lt;/p&gt;&lt;p&gt;The Throttling of Compounded GLP-1sFDA vs Telehealth, What’s Really HappeningThe Truth About “Research Peptides”The Rule That Created the Black Market If You Rely on This, Here’s What’s ComingWhy They Want You Back on Branded DrugsRetatrutide Might Be the Most Powerful YetThe Data That Changes Everything (Diabetes + Weight Loss)What Comes After GLP-1s, The Next Wave&lt;/p&gt;
</description>

Access to compounded and research-grade GLP-1s may be tightening, as comments from Robert F. Kennedy Jr. signal increased enforcement and a push back toward branded medications. At the same time, new data on retatrutide shows powerful results for people with type 2 diabetes, while drug companies are already developing next-generation therapies beyond GLP-1s. Todat&#39;s topics:The Throttling of Compounded GLP-1sFDA vs Telehealth, What’s Really HappeningThe Truth About “Research Peptides”The Rule That Created the Black Market If You Rely on This, Here’s What’s ComingWhy They Want You Back on Branded DrugsRetatrutide Might Be the Most Powerful YetThe Data That Changes Everything (Diabetes + Weight Loss)What Comes After GLP-1s, The Next Wave

On The Pen GLP-1 News

Retatrutide Is Too Good… And That’s The Problem

Retatrutide Is Too Good… And That’s The Problem

Description